Data | Ora | Fonte | Titolo | Simbolo | Compagnia |
03/06/2024 | 12:01 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:CRBU | Caribou Biosciences Inc |
03/06/2024 | 01:00 | GlobeNewswire Inc. | Caribou Biosciences Presents Encouraging Clinical Data from CB-010 ANTLER Phase 1 Trial in Second-line LBCL Patients at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting | NASDAQ:CRBU | Caribou Biosciences Inc |
30/05/2024 | 22:01 | GlobeNewswire Inc. | Caribou Biosciences to Host KOL Discussion with Webcast from the 2024 ASCO Annual Meeting and Participate in Upcoming Investor Conferences | NASDAQ:CRBU | Caribou Biosciences Inc |
07/05/2024 | 22:05 | GlobeNewswire Inc. | Caribou Biosciences Reports First Quarter 2024 Financial Results and Provides Business Update | NASDAQ:CRBU | Caribou Biosciences Inc |
01/05/2024 | 22:05 | GlobeNewswire Inc. | Caribou Biosciences to Participate in Upcoming Investor Conferences | NASDAQ:CRBU | Caribou Biosciences Inc |
24/04/2024 | 16:00 | GlobeNewswire Inc. | Caribou Biosciences to Present Initial Dose Expansion Data from CB-010 ANTLER Phase 1 Trial in r/r B-NHL at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting | NASDAQ:CRBU | Caribou Biosciences Inc |
15/04/2024 | 15:00 | GlobeNewswire Inc. | Caribou Biosciences Announces Oral Presentation on In Vivo Cas12a chRDNA Genome Editing at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) | NASDAQ:CRBU | Caribou Biosciences Inc |
04/04/2024 | 22:00 | GlobeNewswire Inc. | Caribou Biosciences Expands Clinical Development of CB-010 with FDA Clearance of IND in Lupus | NASDAQ:CRBU | Caribou Biosciences Inc |
11/03/2024 | 22:08 | Edgar (US Regulatory) | Form S-8 - Securities to be offered to employees in employee benefit plans | NASDAQ:CRBU | Caribou Biosciences Inc |
11/03/2024 | 21:25 | Edgar (US Regulatory) | Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] | NASDAQ:CRBU | Caribou Biosciences Inc |
11/03/2024 | 21:05 | GlobeNewswire Inc. | Caribou Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update | NASDAQ:CRBU | Caribou Biosciences Inc |
05/03/2024 | 22:30 | GlobeNewswire Inc. | Caribou Biosciences to Present Preclinical Data on CB-012, an Allogeneic Anti-CLL-1 CAR-T Cell Therapy, at the American Association for Cancer Research (AACR) Annual Meeting | NASDAQ:CRBU | Caribou Biosciences Inc |
22/02/2024 | 23:28 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:CRBU | Caribou Biosciences Inc |
10/01/2024 | 22:18 | Edgar (US Regulatory) | Form 3/A - Initial statement of beneficial ownership of securities: [Amend] | NASDAQ:CRBU | Caribou Biosciences Inc |
09/01/2024 | 22:07 | Edgar (US Regulatory) | Form 3 - Initial statement of beneficial ownership of securities | NASDAQ:CRBU | Caribou Biosciences Inc |
08/01/2024 | 22:18 | Edgar (US Regulatory) | Form SC 13G - Statement of acquisition of beneficial ownership by individuals | NASDAQ:CRBU | Caribou Biosciences Inc |
07/01/2024 | 17:00 | GlobeNewswire Inc. | Caribou Biosciences Appoints Tim Kelly as Chief Technology Officer and Highlights Multiple Clinical Catalysts Expected in 2024 | NASDAQ:CRBU | Caribou Biosciences Inc |
13/12/2023 | 12:30 | IH Market News | Cal-Maine Avian Flu Outbreak Impact, Amgen Hikes Dividend For Twelfth Year, and Latest Updates | NASDAQ:CRBU | Caribou Biosciences Inc |
13/12/2023 | 00:26 | Dow Jones News | Caribou Biosciences Shares Rise 4.1% as FDA Approves Lymphoma Trial | NASDAQ:CRBU | Caribou Biosciences Inc |
12/12/2023 | 22:02 | GlobeNewswire Inc. | Caribou Biosciences Provides Regulatory Update on CB-010 Pivotal Plan with Phase 3 Trial Initiation Expected by YE 2024 | NASDAQ:CRBU | Caribou Biosciences Inc |
17/11/2023 | 22:06 | Edgar (US Regulatory) | Form 10-Q/A - Quarterly report [Sections 13 or 15(d)]: [Amend] | NASDAQ:CRBU | Caribou Biosciences Inc |
07/11/2023 | 22:03 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] | NASDAQ:CRBU | Caribou Biosciences Inc |
07/11/2023 | 22:00 | GlobeNewswire Inc. | Caribou Biosciences Reports Third Quarter 2023 Financial Results and Provides Business Update | NASDAQ:CRBU | Caribou Biosciences Inc |
06/11/2023 | 14:00 | GlobeNewswire Inc. | Caribou Biosciences Announces Appointment of Sundar Jagannath, MD, to its Scientific Advisory Board | NASDAQ:CRBU | Caribou Biosciences Inc |
18/10/2023 | 14:00 | GlobeNewswire Inc. | Caribou Biosciences Announces FDA Clearance of IND Application for CB-012, an Allogeneic Anti-CLL-1 CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia | NASDAQ:CRBU | Caribou Biosciences Inc |
27/09/2023 | 14:00 | GlobeNewswire Inc. | Caribou Biosciences Appoints Reigin Zawadzki as Chief People Officer | NASDAQ:CRBU | Caribou Biosciences Inc |
08/08/2023 | 22:00 | GlobeNewswire Inc. | Caribou Biosciences Reports Second Quarter 2023 Financial Results and Provides Business Update | NASDAQ:CRBU | Caribou Biosciences Inc |
14/07/2023 | 23:31 | Edgar (US Regulatory) | Form 424B5 - Prospectus [Rule 424(b)(5)] | NASDAQ:CRBU | Caribou Biosciences Inc |
14/07/2023 | 22:22 | Edgar (US Regulatory) | Form 8-K/A - Current report: [Amend] | NASDAQ:CRBU | Caribou Biosciences Inc |
14/07/2023 | 13:51 | IH Market News | Friday’s Wall Street Highlights: JPMorgan Chase, Coinbase, UPS, Theseus Pharmaceuticals, and more | NASDAQ:CRBU | Caribou Biosciences Inc |